

Practitioner's Docket No. MPI00-452P1RM

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: O'Keefe, Theresa et al.  
Application No.: 10/060,714                      Group No.: 1644  
Filed: January 30, 2002                      Examiner: Schwardon, Ronald B.  
For: HYBRID ANTIBODIES AND USES THEREOF

**Mail Stop Amendment**  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**List of Sections Forming Part of This Information Disclosure Statement**

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ Copy of Listed Information Item Accompanying This Statement (A41, B37, C3-C5)
3. ☒ Forms PTO/SB/08A and PTO/SB/08B (substitute for Form PTO-1449)

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

- ☒ deposited with the United States Postal Service in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

- ☒ with sufficient postage as first class mail.


☐ as "Express Mail Post Office to Address"  
Mailing Label No.

**TRANSMISSION**

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Date: December 6, 2004

**Signature**

  
Sean Hunziker/Beverly Sotiropoulos  
(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

### **Preliminary Statements**

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

### **Copies of Listed Information Items Accompanying This Statement**

Legible copies of the items listed in Form PTO/SB/08A and Form PTO/SB/08B (substitute for Form PTO-1449) accompany this information statement.

December 6, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By Tracy M. Sioussat  
Tracy M. Sioussat, Ph.D.  
Registration No. 50,609  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone - 617-374-7679  
Facsimile - 617-551-8820



Practitioner Docket No. MPI00-452P1RM

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: O'Keefe, Theresa et al.  
Application No.: 10/060,714                      Group No.: 1644  
Filed: January 30, 2002                      Examiner: Schwardon, Ronald B.  
For: HYBRID ANTIBODIES AND USES THEREOF

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement submitted herewith is being filed:

☒ Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

**OR**

☐ *After* three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

- (1) a final action under Section 1.113,
- (2) a notice of allowance under Section 1.311, or

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

☒ deposited with the United States Postal Service in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. SECTION 1.8(a)**


**37 C.F.R. SECTION 1.10\***

☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Addressee"  
Mailing Label No.

**TRANSMISSION**

☐ transmitted by facsimile to the Patent and Trademark Office.

  
Signature  
Sean Hunziker/Beverly Sotiropoulos  
(type or print name of person certifying)

Date: December 6, 2004

**\*WARNING:** Each paper or fee filed by "Express Mail" *must* have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will *not* be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**Practitioner's Docket No. MPI00-452P1RM**

(3) an action that otherwise closes prosecution in the application

whichever occurs first.

☐ Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

☐ Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

☐ No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

**OR**

☐ The information disclosure statement transmitted herewith is being filed *after* a final action under Section 1.113, or a notice of allowance under Section 1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee.

☐ In accordance with the requirements of 37 C.F.R. Section 1.97(d):

A. ☐ Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

B. ☐ Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

C. ☐ No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

Practitioner's Docket No. MPI00-452P1RM

**FEE PAYMENT**

3. ☐ The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).

☒ Applicant believes no fee is due in connection with this submission. However, if any fees are due, please charge Account 501668.

Fee due \$0.00

**METHOD OF PAYMENT OF FEE**

4. ☐ Attached is a check in the amount of \$ \_\_\_\_\_ .  
☐ Charge Account No. 501668 in the amount of \$00 .  
☐ A duplicate of this request is attached.

If any fees are due, please charge Account 501668.

December 6, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By

Tracy M. Sioussat

Tracy M. Sioussat, Ph.D.

Registration No. 50,609


40 Landsdowne Street

Cambridge, MA 02139

Telephone - 617-374-7679

Facsimile - 617-551-8820





Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/060,714
				<b>Filing Date</b>	January 30, 2002
				<b>First Named Inventor</b>	O'Keefe, Theresa
				<b>Group Art Unit</b>	1644
				<b>Examiner Name</b>	Schwadron, Ronald B.
				<b>Attorney Docket Number</b>	MPI00-452P1RM
Sheet	1	of	1		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T <sup>2</sup>
	C3	A.P. Lewis et al., "Generation of Humanized Monoclonal Antibodies by 'Best Fit' Framework Selection and Recombinant Polymerase Chain Reaction," <i>The Year in Immunology</i> , Vol. 7 (1993) pp 110-118	
	C4	M. Little et al., "Of Mice and Men: Hybridoma and Recombinant Antibodies," <i>Immunology Today</i> , Vol. 21, No. 8 (Aug. 1, 2000) pp 364-370	
	C5	G. Winter et al., "Humanized Antibodies," <i>Immunology Today</i> , Vol. 14, No. 6 (1993) pp 243-246	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Did not receive any NPLs.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.